Filing Details
- Accession Number:
- 0001209191-18-064086
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-26 16:09:47
- Reporting Period:
- 2018-12-21
- Accepted Time:
- 2018-12-26 16:09:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1645460 | Cue Biopharma Inc. | CUE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
897744 | A Christopher Marlett | 2425 Cedar Springs Road Dallas TX 75201 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-12-21 | 17,200 | $4.53 | 51,434 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 9,000 | Direct | |
Common Stock | 1,017,973 | Indirect | See footnote |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.33 to $4.66, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4
- Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee.
- The record owner of these securities is MDB Capital Group, LLC ("MDB"). The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes.